MDMA

MDMA is an empathogen or entactogen, a class distinct from classical psychedelics, with a mild stimulant profile. It acts by reversing the monoamine transporters: serotonin, dopamine and noradrenaline. The plate describes it as a substance that opens the heart and trust more than it dismantles perception.

Pharmacology

MDMA is a substrate of the SERT, DAT and NET transporters. It enters the neuron, reverses their function and triggers a massive release of serotonin (its main effect), as well as dopamine and noradrenaline. Its distinctive signature is an increase in oxytocin, hence empathogenesis, and a release of vasopressin, cortisol and prolactin. The plate summarises the mechanism as a reversal of SERT, DAT and NET, a massive release of 5-HT, DA and NA, an oxytocin and trust component, then a post-exposure depletion responsible for fatigue, anhedonia and comedown.

Effect on brain networks

MDMA increases connectivity between socio-emotional networks and alters the processing of fear, reward and social cognition. The plate details a relative reduction in the activity and cohesion of the default mode network (DMN), with decreased amygdala reactivity to threatening cues: increased socio-emotional connectivity, attenuated amygdala (threat or fear), increased functional synchronisation, and an after-effect of monoaminergic depletion.

Functional consequences

Subjectively, the plate reports an experience of emotional openness, trust and social connection, with mild stimulation and slight sensory amplification. Listed are: increased empathy, compassion and trust; a feeling of deep connection to others; reduced rumination and emotional avoidance; improved mood and wellbeing; slightly amplified sensory perception; moderate stimulant effects (energy, alertness, sociability); therapeutic research, notably in post-traumatic stress disorder and social anxiety, with an application underway at the FDA.

Reported subjective effects

The plate cites: love, empathy and connection; emotional openness, trust and intimacy; euphoria, joy and wellbeing; slightly amplified sensory perception; mental clarity; mild time alteration; descent and comedown possible on day 1 to day 3.

Empathogenesis as subtraction

The plate already notes that MDMA attenuates amygdala reactivity to threat cues. A finer reading draws a consequence from this: the warmth of the first times is less an addition than a subtraction. A nearby body carries a default valence, a vigilance, a threat appraisal of amygdalar origin. Empathogenesis (oxytocin, serotonergic tone) acts as a mask that pushes this threat-prior below the threshold; what is lived as love and trust is first of all the lowering of a guard.

This reading is confirmed above all by its failure. In a depleted or saturated system, when the empathogenic effect is gone (the plateau without the warmth) while sympathetic arousal still runs full (clenched jaw, disorganised thought, near a physiological limit), the suppression drops but the amplification stays. The threat-prior regains a high precision weight and can rise into intrusive content: nearby bodies, sometimes even loved ones, are then treated as dangers to be neutralised. This is not an effect foreign to the molecule, it is what it normally neutralises, made visible by its own failure. This mechanism sheds light on why sessions where the magic is gone can turn dysphoric, and why stacking another serotonergic or psychedelic (for example 2C-B) onto an already-taxed system tends to precipitate this tipping rather than bring the warmth back.

Duration and tolerance

Onset is between 30 and 60 minutes, the peak lasts 1 to 2 hours, total duration is 3 to 6 hours, and the comedown or after-effect runs from 24 to 72 hours (fatigue, anhedonia, irritability possible). The plate underlines fast tolerance or the progressive loss of the empathogenic effect (the magic gone): recommended spacing is at least 2 to 3 months, ideally more, to limit cumulative toxicity.

Harm reduction

The plate highlights hyperthermia, dehydration and hyponatremia (notably in contexts of exertion, for example at festivals), cardiovascular risk and increased heart rate, serotonergic neurotoxicity at high or repeated doses, and a risk of slipping into compulsive use. It also stresses the loss of the desired effect (magic gone) which pushes toward higher doses, as well as purity or adulteration (testing products; risk of PMA/PMMA, methamphetamine, cathinones), and a serotonergic risk when combined with MAOIs or SSRIs.

Sources

• Merck, patent by Anton Köllisch, 1912 (MDMA appears there as a synthesis intermediate).
• Alexander Shulgin, rediscovery in the 1970s and psychotherapy work around Adam.
• Clinical research on MDMA in post-traumatic stress disorder (MAPS trials, FDA rejection noted in 2024).
• Literature on serotonergic neurotoxicity and hyponatremia associated with MDMA.